Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Stereotactic Radiotherapy System Approved For BC

FDA news release; 2017 Dec 22

The FDA has approved a new noninvasive stereotactic radiotherapy system to treat cancer in breast tissue.

Indications: The GammaPod system is intended for use in the noninvasive stereotactic delivery of a radiation dose to a portion of the breast in conjunction with breast conserving treatment.

Administration: The system uses thousands of focused beams of radiation from 36 rotating radioactive Cobalt-60 sources in combination with a 2-layer, vacuum-assisted cup that immobilizes the breast to achieve a more accurate delivery of radiation.

Efficacy and safety: Approval is based on a study of 17 individuals that showed the prescribed dose was delivered to the breast tumor with minimal radiation-induced side effects such as skin redness or erythema.


FDA clears stereotactic radiotherapy system for use in treating breast cancer [news release]. Silver Spring, MD: FDA. December 22, 2017. Accessed December 31, 2017.

This Week's Must Reads

Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44.

Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04

TAO: Nonwhite ethnicity, limb infection predict poor prognosis, Le Joncour A et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 1885

Thrombolysis for acute ischemic stroke safe in GI malignancy, Inohara T et al. Circulation. 2018 Nov 6;138[suppl 1], Abstract A12291

Must Reads in Breast Cancer

Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04

Advanced age not linked with risk from nipple-sparing mastectomy, Cox S et al. and Bartholomew AJ et al. Session SF310 ACS Clinical Congress 2018

Avoiding topical agents prior to RT may be unnecessary, Baumann BC et al. JAMA Oncol. 2018 Oct 18. doi: 10.1001/jamaoncol.2018.4292

Men with MBC have a similar prognosis compared with women, Sirieix et al. ESMO 2018, Abstract 294PD; Reinisch et al. ESMO 2018, Abstract 273PD